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LETTERS TO THE EDITOR
Effect of obesity on PD versus
HD survival: Is caloric intake
the discriminating factor?
To the Editor: Higher body mass index (BMI) and its
positive association with dialysis patients’ survival has be-
come an area of interest [1]. Abbott et al [2] have recently
published an article suggesting that any paradoxical sur-
vival advantage observed with obesity in hemodialysis
(HD) patients may not be seen in patients on peritoneal
dialysis (PD). This contradicts an earlier report by Sny-
der et al [3], but Abbott et al’s finding is probably more
reflective of the long-term. If the finding by Abbott et al
is to be confirmed (i.e., obesity in PD is not associated
with any long-term survival advantage), then one has to
ask the interesting question as to why there may be a
“paradox within paradox?”
We would like to propose an intriguing and plausible
hypothesis that involves difference in the caloric intake.
In general, all PD patients, obese or nonobese, employ
1.5% to 4.25% of dextrose in their dialysate, often around
the clock, that is estimated to be absorbed at 45% [4]. In
contrast, HD patients are exposed to 1% of dextrose in
their dialysate during the 4-hour, thrice weekly dialysis.
Therefore, the higher caloric intake, rather than obesity,
per se, may account for the better survival of dialysis pa-
tients, and this may help to explain why nonobese patients
on PD may not display any less survival advantage com-
pared with their obese counterparts (Fig. 1). A higher
caloric intake by dialysis patients for many conceivable
reasons may contribute to longer survival. Anyone for a
controlled trial?
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Fig. 1. Hypothesis that caloric intake (dotted arrows) rather than body
composition (large circle represents the obese, small circle represents
the lean) dictates survival on dialysis. In spite of potentially reduced oral
caloric intake by the underweight peritoneal dialysis (PD) patients, the
dextrose in the PD dialysate ensures a minimum “high” caloric intake,
theoretically accounting for a survival no less than the obese PD pa-
tients. Lack of caloric compensation among the underweight hemodial-
ysis patients may explain a reduced survival rate.
On the epithelial-mesenchymal
transition of mesothelial cells
To the Editor: In a recently published review article,
Williams et al [1], on behalf of the Biopsy Registry Study
Group, to which some of us belong, raise several criticisms
regarding the paper published by our group in the New
England Journal of Medicine [2] without first consulting
us or taking into account our opinion. In general, these
comments are not scientifically based and appear to be
personal opinions.
Williams et al remarked only on our data regarding
the down-regulation of cytokeratin expression and the
increase in vimentin expression by effluent mesothelial
cells when compared to “in situ” cells, sentencing that
these markers are modulated by the simple “ex vivo”
culture of mesothelial cells, questioning the epithelial-
mesenchymal transition phenomenon itself. With this
simplistic point of view, the authors left out additional
and much more important markers, which confirmed
the epithelial-mesenchymal transition in our study (i.e.,
down-regulation of E-cadherin, induction of snail nuclear
factor, and changes in integrin expression).
Furthermore, they affirm to be “unable to identify
in vivo similar fibroblastic phenotypic changes in the
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